Influenza, Human: all 2,264 studies

Page 6 of 23. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.

• Self-Administered Nasal Influenza Feasibility StudyCompletedNCT01933048Phase 4Results posted
• Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 YearsCompletedNCT01928472Phase 1Results posted
• Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)CompletedNCT01910519Phase 2Results posted
• Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and AboveCompletedNCT01885117Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and OlderCompletedNCT01884519Phase 3Results posted
• Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and AboveCompletedNCT01880697Phase 3Results posted
• Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and AboveCompletedNCT01879553Phase 2Results posted
• Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of AgeCompletedNCT01879540Phase 2Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and OlderCompletedNCT01878825Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and OlderCompletedNCT01878812Phase 3Results posted
• SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIMCompletedNCT01868334Not applicableResults posted
• Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and AboveCompletedNCT01867021Phase 4Results posted
• Tolerability and Immunogenicity Study of Fluval AB Suspension for InjectionCompletedNCT01863849Phase 4Results posted
• A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01863433Phase 4Results posted
• Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in AdultsCompletedNCT01859143Phase 4Results posted
• A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01857297Phase 4Results posted
• Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of AgeCompletedNCT01857206Phase 3Results posted
• Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.CompletedNCT01855945Phase 1Results posted
• Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in SenegalCompletedNCT01854632Phase 3Results posted
• Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of InfluenzaCompletedNCT01850446Phase 4Results posted
• Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)CompletedNCT01827462Phase 4Results posted
• Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of AgeCompletedNCT01825200Phase 3Results posted
• Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.CompletedNCT01808456Phase 4Results posted
• Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of InfluenzaCompletedNCT01804946Phase 4Results posted
• A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in BangladeshCompletedNCT01797029Phase 3Results posted
• Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With InfluenzaCompletedNCT01793883Phase 2Results posted
• Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) ExposureCompletedNCT01788228Phase 3Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in ChildrenCompletedNCT01776554Phase 2Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy AdultsCompletedNCT01776541Phase 2Results posted
• Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)CompletedNCT01773928Phase 3Results posted
• Evaluating Modes of Influenza Transmission Observational Study of Community Acquired InfluenzaCompletedNCT01769430Results posted
• Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly SubjectsCompletedNCT01766921Phase 2Results posted
• Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years OldCompletedNCT01730378Phase 4Results posted
• High Dose Influenza Vaccine in Nursing Home - Pilot StudyCompletedNCT01720277Phase 4Results posted
• Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza VaccineCompletedNCT01719783Phase 1Results posted
• Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 YearsCompletedNCT01712984Phase 3Results posted
• Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of AgeCompletedNCT01711736Phase 3Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345CompletedNCT01702454Phase 3Results posted
• Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.CompletedNCT01691339Phase 4Results posted
• Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)CompletedNCT01691326Phase 4Results posted
• Jet Injection for InfluenzaCompletedNCT01688921Phase 4Results posted
• Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, CanadaCompletedNCT01683630Results posted
• Evaluating Immune Response to Seasonal FluMist in Healthy AdultsTerminatedNCT01673425Not applicableResults posted
• Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving ChemotherapyCompletedNCT01666782Phase 2Results posted
• A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza VaccineCompletedNCT01665807Phase 4Results posted
• From Innovation to Solutions: Childhood Influenza Vaccination PlanningCompletedNCT01664793Not applicableResults posted
• Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban ChildrenCompletedNCT01662583Not applicableResults posted
• Randomized Trial of High Dose Influenza Vaccine in Long Term Care SettingCompletedNCT01654224Phase 4Results posted
• Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly SubjectsCompletedNCT01651104Phase 2Results posted
• Influenza A 2009 H1N1 Challenge Study in Healthy AdultsCompletedNCT01646138Phase 1/2Results posted
• Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle SyringeCompletedNCT01644149Phase 4Results posted
• Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and AboveCompletedNCT01640327Phase 3Results posted
• Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and AboveCompletedNCT01640314Phase 3Results posted
• Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and AboveCompletedNCT01636102Phase 2Results posted
• Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza StrainsCompletedNCT01631110Phase 3Results posted
• Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza StrainsCompletedNCT01631071Not applicableResults posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in AdultsCompletedNCT01626820Phase 3Results posted
• Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza VaccineCompletedNCT01625689Phase 2Results posted
• Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy AdultsCompletedNCT01612000Phase 1/2Results posted
• A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2012/2013 in People Aged 18 Years and AboveCompletedNCT01607112Phase 3Results posted
• Study on the Burden of Influenza-related Hospitalizations and Emergency Room (ER) Visits in Children in SpainCompletedNCT01592799Not applicableResults posted
• A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01591837Phase 4Results posted
• A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in AdultsCompletedNCT01579916Phase 4Results posted
• Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese ToddlersCompletedNCT01577732Phase 3Results posted
• A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza InfectionCompletedNCT01527110Phase 3Results posted
• Early Immune Responses to Inactivated Influenza Vaccine: a Pilot StudyCompletedNCT01522248Not applicableResults posted
• Safety Trial of Live Attenuated Influenza (H7N3) VaccineCompletedNCT01511419Phase 1Results posted
• Safety Trial of Monovalent Whole Virus Influenza (H1N1) VaccineCompletedNCT01507779Phase 1Results posted
• Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual RouteCompletedNCT01488188Phase 1Results posted
• A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and OlderCompletedNCT01440387Phase 3Results posted
• An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in ChildrenCompletedNCT01439360Phase 3Results posted
• Study of Fluzone® Influenza Virus Vaccine 2011-2012 Formulation (Intramuscular Route) Among AdultsCompletedNCT01430819Phase 4Results posted
• A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly AdultsCompletedNCT01427309Phase 4Results posted
• Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in AdultsCompletedNCT01416571Phase 2Results posted
• Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different SuppliersCompletedNCT01412281Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in ChildrenCompletedNCT01379937Phase 3Results posted
• Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BCompletedNCT01362517Phase 3Results posted
• Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™CompletedNCT01358825Phase 4Results posted
• Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) VaccineCompletedNCT01353703Phase 3Results posted
• Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of AgeCompletedNCT01346592Phase 3Results posted
• Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012CompletedNCT01344057Phase 2Results posted
• Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy SubjectsCompletedNCT01342796Phase 2Results posted
• A Comparison of Solid and Soluble Forms of Cold and Influenza RemediesCompletedNCT01332578Phase 4Results posted
• Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in ChildrenCompletedNCT01323946Phase 2Results posted
• Reverse Genetic H9N2 Influenza Vaccine Study in AdultsCompletedNCT01320696Phase 1/2Results posted
• Surveillance for Adverse Events Following Influenza ImmunizationCompletedNCT01318876Results posted
• Evaluating the Use of Oseltamivir for the Treatment of Influenza in AdultsCompletedNCT01314911Not applicableResults posted
• Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of AgeCompletedNCT01310413Phase 3Results posted
• Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young ChildrenCompletedNCT01310400Phase 3Results posted
• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern HemisphereCompletedNCT01306305Phase 4Results posted
• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern HemisphereCompletedNCT01306253Phase 4Results posted
• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern HemisphereCompletedNCT01303510Phase 4Results posted
• Collection and Testing of Respiratory SamplesCompletedNCT01302418Results posted
• A Study of High-Dose Trivalent Inactivated Influenza Vaccine in Adults 50 to 64 Years of AgeCompletedNCT01258595Phase 2Results posted
• Effect of Oseltamivir on Cognitive Function in Subjects With InfluenzaCompletedNCT01249833Phase 4Results posted
• Rapid Empiric Treatment With Oseltamivir Study (RETOS)CompletedNCT01248715Phase 4Results posted
• Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in ChildrenCompletedNCT01246999Phase 4Results posted
• Study of Quadrivalent Influenza Vaccine Among ChildrenCompletedNCT01240746Phase 3Results posted
• Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and ElderlyCompletedNCT01232868Not applicableResults posted
• A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With InfluenzaCompletedNCT01231620Phase 3Results posted

← Influenza, Human overview